JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice

  • 0Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research +

|

July 30, 2024

|

July 30, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Poly (ADP-ribose) polymerase inhibitor maintenance therapy (mPARPi) shows improved outcomes in advanced ovarian cancer patients with homologous recombination deficiency signature (HRDsig) positivity. HRDsig status is a better predictor of mPARPi benefit than BRCA1/2 alterations.

Area Of Science

  • Oncology
  • Genetics
  • Pharmacology

Background

  • PARP inhibitor maintenance therapy (mPARPi) is a standard treatment for advanced ovarian cancer.
  • Biomarker status, including BRCA1/2 alterations (BRCAalt) and homologous recombination deficiency signature (HRDsig), influences treatment response.
  • Real-world data is crucial for understanding mPARPi effectiveness across diverse patient populations.

Purpose Of The Study

  • To compare the effectiveness of mPARPi in real-world practice.
  • To evaluate mPARPi efficacy based on biomarker status (BRCAalt and HRDsig) in advanced ovarian cancer.
  • To determine if HRDsig is a better predictor of mPARPi benefit than BRCAalt.

Main Methods

  • Retrospective analysis of a US-based de-identified ovarian cancer Clinico-Genomic Database (01/2015-03/2023).
  • Inclusion of patients with advanced ovarian cancer receiving first-line platinum-based chemotherapy with or without mPARPi.
  • Comparison of real-world progression-free survival (rwPFS) and overall survival (rwOS) using propensity score-weighted Cox models stratified by biomarker status.

Main Results

  • mPARPi was associated with favorable rwPFS in BRCAalt patients (HR, 0.48) and BRCA wild-type (WT) patients (HR, 0.76).
  • HRDsig(+) patients receiving mPARPi showed significantly favorable rwPFS (HR, 0.36) and numerically favorable rwOS (HR, 0.46).
  • No significant benefit from mPARPi was observed in HRDsig(-) patients, irrespective of BRCA status.

Conclusions

  • HRDsig status is a stronger predictor of mPARPi benefit than BRCAalt status in advanced ovarian cancer.
  • Patients with HRDsig(+) status benefit from mPARPi, even if they have BRCA-WT status.
  • HRDsig negativity suggests a lack of benefit from mPARPi, regardless of BRCAalt status.